CN100516061C - 作为nmda受体配体的吡啶衍生物 - Google Patents

作为nmda受体配体的吡啶衍生物 Download PDF

Info

Publication number
CN100516061C
CN100516061C CNB028222512A CN02822251A CN100516061C CN 100516061 C CN100516061 C CN 100516061C CN B028222512 A CNB028222512 A CN B028222512A CN 02822251 A CN02822251 A CN 02822251A CN 100516061 C CN100516061 C CN 100516061C
Authority
CN
China
Prior art keywords
formula
compound
dihydro
pyridin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028222512A
Other languages
English (en)
Chinese (zh)
Other versions
CN1585762A (zh
Inventor
A·阿拉尼恩
B·布特尔曼
M-P·埃茨奈德哈特
E·皮那德
R·维勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1585762A publication Critical patent/CN1585762A/zh
Application granted granted Critical
Publication of CN100516061C publication Critical patent/CN100516061C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028222512A 2001-11-09 2002-11-02 作为nmda受体配体的吡啶衍生物 Expired - Fee Related CN100516061C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126467 2001-11-09
EP01126467.8 2001-11-09

Publications (2)

Publication Number Publication Date
CN1585762A CN1585762A (zh) 2005-02-23
CN100516061C true CN100516061C (zh) 2009-07-22

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028222512A Expired - Fee Related CN100516061C (zh) 2001-11-09 2002-11-02 作为nmda受体配体的吡啶衍生物

Country Status (16)

Country Link
US (1) US6831087B2 (https=)
EP (1) EP1448547B1 (https=)
JP (1) JP4188837B2 (https=)
KR (1) KR100589995B1 (https=)
CN (1) CN100516061C (https=)
AR (1) AR037221A1 (https=)
AT (1) ATE293619T1 (https=)
AU (1) AU2002351816B8 (https=)
BR (1) BR0213977A (https=)
CA (1) CA2467973C (https=)
DE (1) DE60203820T2 (https=)
ES (1) ES2240829T3 (https=)
MX (1) MXPA04004308A (https=)
PL (1) PL369544A1 (https=)
RU (1) RU2303037C2 (https=)
WO (1) WO2003040128A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
RU2320654C1 (ru) * 2006-05-24 2008-03-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
WO2009065922A2 (de) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)
WO2025124571A1 (zh) * 2023-12-14 2025-06-19 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ATE524440T1 (de) * 1998-05-25 2011-09-15 Abbott Gmbh & Co Kg Heterocyclische substituierte amide, deren herstellung und anwendung
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Quantitative structure activity relationship in ...... SAXENA, ANIL Kl ET AL.Indian Journal of Chemistry,Vol.19 No.10. 1980 *

Also Published As

Publication number Publication date
RU2303037C2 (ru) 2007-07-20
US6831087B2 (en) 2004-12-14
CA2467973C (en) 2009-09-01
DE60203820T2 (de) 2006-02-23
RU2004117595A (ru) 2006-01-10
MXPA04004308A (es) 2004-08-11
EP1448547A1 (en) 2004-08-25
AU2002351816B2 (en) 2008-03-06
JP4188837B2 (ja) 2008-12-03
ATE293619T1 (de) 2005-05-15
US20030119870A1 (en) 2003-06-26
CN1585762A (zh) 2005-02-23
PL369544A1 (en) 2005-05-02
CA2467973A1 (en) 2003-05-15
EP1448547B1 (en) 2005-04-20
BR0213977A (pt) 2004-08-31
ES2240829T3 (es) 2005-10-16
AU2002351816B8 (en) 2008-04-03
JP2005513004A (ja) 2005-05-12
AR037221A1 (es) 2004-10-27
WO2003040128A1 (en) 2003-05-15
KR20050042252A (ko) 2005-05-06
KR100589995B1 (ko) 2006-06-19
DE60203820D1 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
CN100516061C (zh) 作为nmda受体配体的吡啶衍生物
JP6767875B2 (ja) Ｔｇｆ−ベータ阻害剤としての２，３−二置換ピリジン化合物および使用方法
EP3461821B1 (en) Indole carboxamide compounds useful as kinase inhibitors
CN100436427C (zh) 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
TW504508B (en) Atropisomers of 3-aryl-4(3h)-quinazolinones
US20040106616A1 (en) Substituted quinazolin-4-ylamine analogues
TW444013B (en) Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia
JP2019048878A (ja) Ｋｉｔに関連する疾患を治療するために有用な組成物
JP7660604B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミド酢酸塩の調製
MX2015006437A (es) Inhibidores de la enzima catecol-o-metiltransferasa (comt).
BR122023004130B1 (pt) Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1
TW200413331A (en) Small molecule PI 3-kinase inhibitors and methods of their use
CN102295643A (zh) 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
JP2000504713A (ja) キナゾリン化合物
TW201940166A (zh) 作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
CN109790144A (zh) 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
AU2002351816A1 (en) Pyridine Substituted Isoquinoline Derivatives
CN110831937A (zh) 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物
CN105008347A (zh) 作为钾离子通道抑制剂的异喹啉类化合物
TW202140446A (zh) 喹啉基膦氧化合物及其組合物和用途
US5618821A (en) Therapeutic phenoxyalkylheterocycles
US5763461A (en) Therapeutic phenoxyalkylheterocycles
JP3035745B2 (ja) 縮合チオフェン誘導体
BR112015030101B1 (pt) Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1
JPS61246182A (ja) ピリジン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090722

Termination date: 20101102